UNSPSC 51391708: Denopamine

This classification denotes a beta-adrenergic agonist with the molecular formula C18H23NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V5F60UPD8P, chemically known as (-)-(r)-alpha-(((3,4-dimethoxyphenethyl)amino)methyl)-p-hydroxybenzyl alcohol but generally known as denopamine, which bears US NIH Compound Identifier 71754. European Medicines Agency schedules Denopamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06977MIG.

UNSPSC 51391708 Denopamine is a Commodity code that state and local governments procure for emergency response and public health initiatives, though recent solicitations show material mismatch with the code's nominal pharmaceutical scope. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure naloxone (an opioid antagonist) and drug deactivation systems—not denopamine—for community health support, with quarterly deliveries required and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information about direct contracting between state pharmacy benefit programs and manufacturers—a procurement mechanism unrelated to denopamine acquisition. Issuing bodies under this code include county health departments and state HHS agencies; the recent record shows activity from Florida county government and the Texas state health agency, both oriented toward community health and pharmacy benefit management rather than single-drug procurement.

Geographic activity is concentrated in Florida and Texas based on the two recent solicitations. No other states appear in the source record. Seminole County's IFB (due July 26, 2023, posted June 30, 2026) represents the only concrete procurement opportunity directly aligned to pharmaceutical product acquisition; the Texas RFI functions as preliminary market research rather than a formal competitive solicitation with binding timelines or award values. The source provides no information about denopamine procurement activity specifically, and the code shows limited recent state and local engagement overall—the two opportunities posted relate to naloxone/drug deactivation systems and pharmacy benefit program design, neither of which maps to denopamine as a standalone therapeutic product.